Randomized Controlled Trial Assessing the Impact of Routine "Oncologist-supportive Care Team" Consultation on the Use of an Additional Line of Chemotherapy in Metastatic Breast Cancer Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 5
- 主要终点
- Rate of prescriptions for a 4th or 5th line of chemotherapy
研究概览
简要总结
The purpose of this study is to assess the impact of systematic "clinical cancer department/supportive care department" consultation meetings, versus standard care, on the prescription of an additional line of chemotherapy in patients with metastatic breast cancer and visceral involvement after 3 or 4 lines of chemotherapy.
This is a prospective paucicentric open label randomized controlled study with 2 parallel arms.
Eligible patients will be randomly assigned to either arm "Study group" or "Standard care".
The number of patients required to demonstrate a 30% reduction of the number of prescriptions for an additional line chemotherapy, assuming an alpha risk of 5% and 80% power, is 100 (50 in each arm).
详细描述
The hypothesis tested is that systematic routine consultation between the supportive care team and clinical oncologists will allow more efficient utilization of supportive care by metastatic breast cancer patients, and will reduce the isolation of physicians involved in the management of these patients. Physicians will then be able to help the patients make realistic decisions for the best possible quality of life and in full accordance with their preferences.
The DISSPO (Department of Interdisciplinary Supportive Care for Cancer Patients) focuses on psycho-oncology, pain evaluation and treatment, palliative care, social service, dietary guidance and physiotherapy. Usually, visits with the DISSPO are arranged when the patients need supportive care but are not included in routine care. In this study, contacts between clinical oncologists and supportive care staff will be formalized and systematized. A specific visit called "supportive care visit" will be organized to investigate the needs of the patient so that a personalized care plan can be proposed. Moreover, a consultation between the referring oncologist and the DISSPO will be organized at least once a month.
Besides the main objective of this study (see brief summary), there are secondary objectives which are to evaluate the impact of systematic "Clinical cancer department/Supportive care department" consultation meetings versus standard care on:
- the use of supportive care
- symptom control
- anxiety-depression levels
- quality of life
- patient representations (adaptation to the disease and locus of control)
- patient perception of social support
- patient satisfaction with the care
- impact of disease on the family
- satisfaction of the referring oncologist
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Woman aged >= 18 years
- •Metastatic breast cancer with visceral involvement
- •Patient requiring a 3rd or a 4th line of chemotherapy
- •Patient followed at Léon Bérard Cancer Center
- •Patient affiliated with social security
- •Patient able to read and write French
- •Written, voluntary, informed consent
排除标准
- •Ongoing chemotherapy other than third or fourth line
- •Only skin or bone metastasis
- •Follow-up impossible for social, geographical, familial or psychological reasons
- •Patient deprived of freedom
- •Pregnant or lactating woman
结局指标
主要结局
Rate of prescriptions for a 4th or 5th line of chemotherapy
时间窗: At the time of progression on 3rd or 4th line of chemotherapy.
When patients progress under 3rd or 4th line of chemotherapy, rate of prescriptions for a 4th or 5th line will be collected.
次要结局
- Evaluation of the number and type of DISSPO interventions(During the period of inclusion in the study: between the inclusion and the time of progression on 3rd or 4th line of chemotherapy)
- Self-evaluation of adaptation and of the locus of control using the CLCS scale.(Self-administered questionnaire at inclusion, at 6 months and 12 months post-inclusion, at the end and 3 months after the end of the 3rd or 4th line of chemotherapy.)
- Self-evaluation of satisfaction with care using the F-PMH/PSQ MD scale(Self-administered questionnaire at inclusion, at 6 months and 12 months post-inclusion, at the end and 3 months after the end of the 3rd or 4th line of chemotherapy.)
- Self-evaluation of satisfaction by the referring physician using the Likert scale(Self-administered questionnaire at 6 months and 12 months post-inclusion, at the end and 3 months after the end of the 3rd or 4th line of chemotherapy.)
- Self-evaluation of symptom control using the Edmonton scale(Self-administered questionnaire at inclusion, at 6 months and 12 months post-inclusion, at the end and 3 months after the end of the 3rd or 4th line of chemotherapy)
- Self-rating of anxiety-depression using the HADS scale(Self-administered questionnaire at inclusion, at 6 months and 12 months post-inclusion, at the end and 3 months after the end of the 3rd or 4th line of chemotherapy.)
- Self-evaluation of quality of life using the QLQC30 scale.(Self-administered questionnaire at inclusion, at 6 months and 12 months post-inclusion, at the end and 3 months after the end of the 3rd or 4th line of chemotherapy.)
- Self-evaluation of social support using the QSSP scale(Self-administered questionnaire at inclusion, at 6 months and 12 months post-inclusion, at the end and 3 months after the end of the 3rd or 4th line of chemotherapy.)
- Self-evaluation of the impact of disease on family using the GHQ28 scale(Self-administered questionnaire at inclusion, at 6 months and 12 months post-inclusion, at the end and 3 months after the end of the 3rd or 4th line of chemotherapy.)